Syndax Pharmaceuticals, Inc. · NASDAQ:SNDX

Syndax Pharmaceuticals — Q1 2023 Earnings Presentation

14 slides from Syndax Pharmaceuticals's earnings presentation, May 8, 2023

  1. Slide 1: Determined to realize a future in which people with cancer live longer and better

    Determined to realize a future in which people with cancer live longer and better than ever before 1Q23 CORPORATE PRESENTATION | MAY 8, 2023

  2. Slide 2: Forward-looking statements disclosure

    Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referenci

  3. Slide 3: Revumenib and axatilimab on-track to file potential marketing applications in 2023

    Revumenib and axatilimab on-track to file potential marketing applications in 2023 with several opportunities for expansion Revumenib Corporate Axatilimab and Menin-KMT2A Anti-CSF-1R Pipeline disruption Expand within acute leukemia and Expand into earlier lines of cGVHD Expand pipeline through BD be

  4. Slide 4: Pivotal AUGMENT-101 trial: Expecting KMT2Ar topline data in 3Q23

    Pivotal AUGMENT-101 trial: Expecting KMT2Ar topline data in 3Q23, enrollment completion for mNPM1 in 2H23 Phase 1: Dose Phase 2: Ongoing Pivotal Trials Expected Milestones Escalation KMT2Ar KMT2Ar Enrollment AUGMENT-101-2A: KMT2Ar ALL sufficient for filing3 Topline data 3Q23 Adult and ped1 AUGMENT-1

  5. Slide 5: Phase 1 data from AUGMENT-101 published in Nature

    Phase 1 data from AUGMENT-101 published in Nature We found an encouraging clinical benefit, with deep molecular remissions and minimal toxicities, in a heavily pretreated population of both children and adults with advanced acute 1 Best Response Efficacy Pop; n = 60 (%) leukemia. 2 Response Overall

  6. Slide 6: Trials underway to establish revumenib as a backbone of treatment for mNPM1 or KMT2Ar acute leukemia

    Trials underway to establish revumenib as a backbone of treatment for mNPM1 or KMT2Ar acute leukemia Relapsed/Refractory Front-Line Maintenance Revumenib Development INTERCEPT trial Validates use of menin Validates the use of menin AUGMENT-101: allows pts to inhibition in NPM1 and inhibition with Tr

  7. Slide 7: Revumenib expansion opportunities in acute leukemia and solid tumors

    Revumenib expansion opportunities in acute leukemia and solid tumors have potential to add meaningful value Est. US market opportunity for Potential first/best-in-class agent mNPM1 and KMT2Ar AML Eligible • Clear activity in refractory, advanced patients 3 $4,000 12,000 mNPM1 and KMT2Ar acute leukem

  8. Slide 8: Axatilimab could provide a differentiated, effective, and practice-changing intervention in cGVHD

    Axatilimab could provide a differentiated, effective, and practice- changing intervention in cGVHD 1st Corticosteroids Line Significant 14,000 patients unmet need 2nd JAKAFI® living with remains across Line IMBRUVICA® cGVHD in the US all lines of therapy 3rd REZUROCK® Line U.S. Regulatory approvals

  9. Slide 9: As a CSF-1R inhibitor, axatilimab is well positioned to impact fibrotic and inflammatory processes

    As a CSF-1R inhibitor, axatilimab is well positioned to impact both fibrotic and inflammatory processes CSF-1R mediates pro-inflammatory and pro-fibrotic monocyte/macrophage differentiation and activation1 • Non-overlapping MOA offers potential to benefit patients Blood vessel CSF-1 Circulating CSF-

  10. Slide 10: Axatilimab Phase 1/2 POC trial in cGVHD showed rapid and durable responses

    Axatilimab Phase 1/2 POC trial in cGVHD showed rapid and durable responses Phase 2 cohort Individual responses and durability of Cumulative response rate in highlights Phase 2 cohort cGVHD-involved organs ORR by cycle 82% 7 day 1 FFS at 12 77% months Median time 4 wks to response Responses observed

  11. Slide 11: Axatilimab pivotal trial data expected in mid-2023 with a BLA filing by year-end

    : Axatilimab pivotal trial data expected in mid-2023 with a BLA filing by year-end Inclusion criteria: • 2 years and older1 0.3 mg/kg Q2W Randomization • Recurrent or refractory active R/R cGVHD after ≥ 2 lines of 1:1:1 cGVHD 1 mg/kg Q2W systemic therapy N = ~ 240 Stratification factors: 3 mg/kg Q4W

  12. Slide 12: Axatilimab has the potential to expand into additional high value indications and new geographies

    Axatilimab has the potential to expand into additional high value indications and new geographies Prevalence estimates ~215,000 US, Expansion into ~335,000 WW2 fibrotic indications: IPF POC* init 2H23 >35,000 WW1 Expansion into EU, Japan, ROW ~14,000 US1 Expansion to 1st L cGVHD: Rux combo trial 2H2

  13. Slide 13: Financial highlights and financial guidance

    Financial highlights and financial guidance Ticker SNDX (NASDAQ) Cash and equivalents (at 31 March 2023) $449 million Shares outstanding* (at 31 March 2023) 69.6 million 2023 Operating Expense Guidance 2Q 2023 FY23 (no change) Research and development $38 – $43 million $160 – $175 million Total oper

  14. Slide 14: Thank you. Questions?

    7 Thank you. Questi ons? ge

Syndax Pharmaceuticals — Q1 2023 Earnings Presentation on 6ix